Keratos Therapeutics

Keratos Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for ocular surface diseases. The company's lead program, K-101, is a small molecule being evaluated in Phase 2 clinical trials for the treatment of neurotrophic keratitis, a rare and debilitating corneal disease. Keratos also maintains a pipeline of candidates targeting other ophthalmic conditions, including dry eye disease. Founded by industry veterans with significant experience in ophthalmology drug development, the company focuses on addressing high unmet medical needs through targeted pharmacological interventions. Keratos is headquartered in San Diego, California, and aims to restore ocular health and prevent vision loss in patients worldwide.